Revolutionary One-Time Shot Offers Hope for Type 2 Diabetes Cure
Biotech company Fractyl Health is developing a one-time gene therapy for type 2 diabetes that aims to continuously produce the GLP-1 hormone, eliminating the need for regular injections. The therapy has shown promise in animal studies, reducing fasting blood sugar levels by 70 percent. If successful in human trials, the therapy could offer benefits such as improved medication adherence, better blood sugar regulation, and sustained weight loss. However, challenges such as safety, efficacy, cost, and accessibility need to be addressed.